论文部分内容阅读
目的对重组人脑利钠肽治疗老年慢性心衰急性加重期的临床疗效进行观察分析。方法对2012年4月—2014年4月期间在社旗县中医院接受治疗的80例慢性心衰急性加重期患者进行临床研究,随机分为对照组和研究组,对对照组给予硝普钠进行治疗,对研究组给予重组人脑利钠肽进行治疗,观察比较两组患者的临床疗效。结果研究组患者的治疗总有效率(95.0%)明显高于对照组患者(80.0%),组间差异明显(P<0.05);研究组患者的不良反应总发生率(12.5%)明显低于对照组患者(25%),组间差异明显(P<0.05);两组的左室舒张末期内径(LVEDD)、射血分数(EF)经治疗均获得改善,治疗后研究组的EF值明显高于对照组(P<0.05)。结论使用重组人脑利钠肽治疗老年慢性心衰急性加重期的临床疗效较好,患者的不良反应少,可进一步推广。
Objective To observe and analyze the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of elderly patients with acute exacerbation of chronic heart failure. Methods A total of 80 patients with acute exacerbation of chronic heart failure who were treated in the Social Hospital of Sheqi County from April 2012 to April 2014 were randomly divided into control group and study group, and sodium nitroprusside For treatment, the study group given recombinant human brain natriuretic peptide for treatment, observed and compared the clinical efficacy of two groups of patients. Results The total effective rate (95.0%) in study group was significantly higher than that in control group (80.0%) (P <0.05). The total adverse reaction rate (12.5%) in study group was significantly lower than that in control group In the control group (25%), there was significant difference between the two groups (P <0.05). The LVEDD and EF of the two groups were improved after treatment. The EF of the study group was obviously Higher than the control group (P <0.05). Conclusion The clinical efficacy of recombinant human brain natriuretic peptide in the treatment of elderly patients with acute exacerbation of chronic heart failure is good, and patients have fewer adverse reactions and can be further popularized.